Pharmacologic management of Parkinson disease: Initial therapy

Formulary

Volumn 41, Issue SUPPL., 2006, Pages 4-11

  Pahwa, Rajesh ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMITRIPTYLINE; BENZATROPINE; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOZAPINE; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUDROCORTISONE; MIDODRINE; MONOAMINE OXIDASE B INHIBITOR; PAROXETINE; PERGOLIDE; PRAMIPEXOLE; PROCYCLIDINE; QUETIAPINE; RASAGILINE; ROPINIROLE; SELEGILINE; TOCOPHEROL; TRAZODONE; TRIHEXYPHENIDYL; UBIQUINONE;

BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COMORBIDITY; CONFUSION; CONSTIPATION; DAILY LIFE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DYSKINESIA; FIBROSIS; FUNCTIONAL DISEASE; HALLUCINATION; HUMAN; HYPOTENSION; INSOMNIA; LEG EDEMA; MEMORY DISORDER; MOTOR DYSFUNCTION; NAUSEA; NEUROPROTECTION; ORTHOSTATIC HYPOTENSION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PLEURAL FIBROSIS; PSYCHOSIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; SINUS TACHYCARDIA; SOMNOLENCE; SUSTAINED RELEASE FORMULATION; URINE RETENTION; VOMITING; XEROSTOMIA;

EID: 33748503411     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Chuang C, Waters C. Initial therapy of Parkinson's disease. In: Samuels MA, Feske S, eds. Office Practice of Neurology. 2nd ed. Philadelphia, Pa: Churchill Livingstone; 2003:741-748.
2. Waters CH. Diagnosis and Management of Parkinson's Disease. 3rd ed. Caddo, Okla: Professional Communications, Inc; 2002.
3. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease. A randomized controlled trial. JAMA. 2000;284:1931-1938.
4. Kostic V, Przedborski S, Flaster E, Stemic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology. 1991;41:202-205.
5. Grandas F, Galiano ML, Tabernero C. Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J Neurol. 1999;246:1127-1133.
6. Wu RM, Chiu HC, Wang M, Chen RC. Risk factors on the occurrence of response fluctuations and dyskinesias in Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1993;5:127-133.
7. Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology. 1999;53:1012-1019.
8. Oertel WH. Pergolide vs L-dopa (PELMOPET). Mov Disord. 2000;15(suppl 3):4.
9. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002;287:1653-1661.
10. Whone AL, Watts RL, Stoessl AJ, et al; the REAL-PENT Study Group. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003;54:93-101.
11. Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology. 2003;60:381-389.
12. Fahn S. Presented at: A Comprehensive Review of Movement Disorders for the Clinical Practitioner 11th Annual Course. August 3-6, 2001; Aspen, Colo.
13. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52:1908-1910.
14. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet. 2004;363:1179-1183.
15. Goetz CG, Blasucci L, Stebbins GT. Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow? Neurology. 1999;52:1227-1229.
16. Montastruc JL, Rascol O, Rascol A. A randomized controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up. J Neurol Neurosurg Psychiatry. 1989;52:773-775.
17. Shannon KM, Bennett JP Jr, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology. 1997;49:724-728.
18. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. JAMA. 1997;278:125-130.
19. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61:1044-1053.
20. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology. 1997;49:393-399.
21. Rascol O, Brooks DJ, Korczyn AD, et al, for the 056 Study Group. A 5-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484-1491.
22. Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, Ruggieri S. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. Neurology. 1999;53:364-370.
23. Palhagen S, Heinonen EH, Hagglund J, et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology. 1998;51:520-525.
24. Allain H, Pollak P, Neukirch HC. Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial. Mov Disord. 1993;8(suppl 1):S36-S40.
25. Myllyla VV, Sotaniemi KA, Vuorinen JA, Heinonen EH. Selegiline in de novo parkinsonian patients: the Finnish study. Mov Disord. 1993;8(suppl 1):S41-S44.
26. Eldepryl® [Prescribing Information]. Tampa, Fla: Somerset Pharmaceuticals Inc; July 1998.
27. Speiser Z, Levy R, Cohen S. Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. J Neural Transm Suppl 1998;52:287-300.
28. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59:1937-1943.
29. Lew M, Hauser R, Hurtig H, et al. Long-term efficacy of rasagiline in Parkinson's disease. Mov Disord. 2005;20(suppl 10):S75. Abstract P250.
30. Standaert DG, Young AB. Treatment of central nervous system degenerative disorders: Parkinson's disease. In: Hardman JG, Limbird LE, Molinoff PB, et al, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996:506-513.
31. Blanpied TA, Boeckman FA, Aizenman E, Johnson JW. Trapping channel block of NMDA-activated responses by amantadine and memantine. J Neurophysiol. 1997;77:309-323.
32. Factor SA, Molho ES. Transient benefit of amantadine in Parkinson's disease: the facts about the myth. Mov Disord. 1999;14:515-517.
33. Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA. 2004;291:358-364.
34. Jordan J, Cena V, Prehn JH. Mitochondrial control of neuron death and its role in neurodegenerative disorders. J Physiol Biochem. 2003;59:129-141.
35. Ondo WG. Rasagiline preclinical studies: implications for neuroprotection. Formulary. 2006;41:25-30.
36. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1989;321:1364-1371.
37. Birkmayer W, Knoll J, Riederer P, Youdim MB, Hars V, Marton J. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm. 1985;64:113-127.
38. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993;328:176-183.
39. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol. 1996;39:29-36.
40. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol. 1996;39:37-45.
41. Giladi N, McDermott MP, Fahn S, et al; the Parkinson Study Group. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology. 2001;56:1712-1721.
42. Shoulson I, Oakes D, Fahn S, et al; the Parkinson Study Group. Impact of sustained deprenyl (seleguine) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol. 2002;51:604-612.
43. Finberg JP, Lamensdorf I, Weinstock M, Schwartz M, Youdim MB. Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol. 1999;80:495-499.
44. Tabakman R, Lecht S, Lazarovici P. Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease? Bioessays. 2004;26:80-90.
45. Wan FJ, Lin HC, Huang KL, Tseng CJ, Wong CS. Systemic administration of D-amphetamine induces long-lasting oxidative stress in the rat striatum. Life Sci. 2000;66:PL205-PL212.
46. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61:561-566.
47. Leber P. Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Dis Assoc Disord. 1997;11(suppl 5):S10-S21. Abstract.
48. Hauser R, Lew M, Hurtig H, Ondo W, Wojcieszek J. Early treatment with rasagiline is more beneficial than delayed treatment start in the long-term management of Parkinson's disease. Mov Disord. 2005;20(suppl 10):S75. Abstract P251.
49. Matthews RT, Yang L, Browne S, Baik M, Beal MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A. 1998;95:8892-8897.
50. Muller T, Buttner T, Gholipour AF, Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett. 2003;341:201-204.
51. Shults CW, Oakes D, Kieburtz K, et al; the Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59:1541-1550.